ProQR Therapeutics N.V (PRQR) EBIAT: 2021-2025
Historic EBIAT for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.
- ProQR Therapeutics N.V's EBIAT fell 44.50% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 81.38%. This contributed to the annual value of -$29.7 million for FY2024, which is 1.11% up from last year.
- ProQR Therapeutics N.V's EBIAT amounted to -$12.9 million in Q3 2025, which was up 6.67% from -$13.8 million recorded in Q2 2025.
- ProQR Therapeutics N.V's 5-year EBIAT high stood at -$2.9 million for Q2 2024, and its period low was -$23.5 million during Q3 2022.
- Over the past 3 years, ProQR Therapeutics N.V's median EBIAT value was -$8.9 million (recorded in 2024), while the average stood at -$8.8 million.
- Per our database at Business Quant, ProQR Therapeutics N.V's EBIAT surged by 74.89% in 2023 and then tumbled by 375.55% in 2025.
- Over the past 5 years, ProQR Therapeutics N.V's EBIAT (Quarterly) stood at -$20.9 million in 2021, then skyrocketed by 34.97% to -$13.6 million in 2022, then spiked by 56.52% to -$5.9 million in 2023, then crashed by 68.55% to -$9.9 million in 2024, then tumbled by 44.50% to -$12.9 million in 2025.
- Its EBIAT was -$12.9 million in Q3 2025, compared to -$13.8 million in Q2 2025 and -$10.6 million in Q1 2025.